Physician profile
Sarah Johnson
NPI 1588949465
$914.06
in general payments reported to CMS, 2019-2025
12 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.70 · 2022: $239 · 2023: $197 · 2024: $263 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $212.02 | 2021-2023 | Mounjaro, Jardiance |
| Abbott Laboratories | $183.76 | 2022-2025 | Eterna |
| Abbvie INC. | $136.36 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $104.84 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $63.78 | 2024-2025 | Aristada, Lybalvi |
| Astellas Pharma US INC | $46.24 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $41.98 | 2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $33.06 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.11 | 2024-2025 | Caplyta |
| Boston Scientific Corporation | $30.77 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.06 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.